These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21346337)

  • 1. Reduction of Alzheimer's disease amyloid-β in plasma by hemodialysis and its relation to cognitive functions.
    Kitaguchi N; Kawaguchi K; Nakai S; Murakami K; Ito S; Hoshino H; Hori H; Ohashi A; Shimano Y; Suzuki N; Yuzawa Y; Mutoh T; Sugiyama S
    Blood Purif; 2011; 32(1):57-62. PubMed ID: 21346337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential therapeutic system for Alzheimer's disease: removal of blood Aβs by hemodialzyers and its effect on the cognitive functions of renal-failure patients.
    Kato M; Kawaguchi K; Nakai S; Murakami K; Hori H; Ohashi A; Hiki Y; Ito S; Shimano Y; Suzuki N; Sugiyama S; Ogawa H; Kusimoto H; Mutoh T; Yuzawa Y; Kitaguchi N
    J Neural Transm (Vienna); 2012 Dec; 119(12):1533-44. PubMed ID: 22699459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective study on blood Aβ levels and the cognitive function of patients with hemodialysis: a potential therapeutic strategy for Alzheimer's disease.
    Kitaguchi N; Hasegawa M; Ito S; Kawaguchi K; Hiki Y; Nakai S; Suzuki N; Shimano Y; Ishida O; Kushimoto H; Kato M; Koide S; Kanayama K; Kato T; Ito K; Takahashi H; Mutoh T; Sugiyama S; Yuzawa Y
    J Neural Transm (Vienna); 2015 Nov; 122(11):1593-607. PubMed ID: 26228626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adsorptive filtration systems for effective removal of blood amyloid β: a potential therapy for Alzheimer's disease.
    Kitaguchi N; Kawaguchi K; Yamazaki K; Kawachi H; Sakata M; Kaneko M; Kato M; Sakai K; Ohashi N; Hasegawa M; Hiki Y; Yuzawa Y
    J Artif Organs; 2018 Jun; 21(2):220-229. PubMed ID: 29230564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influx of Tau and Amyloid-β Proteins into the Blood During Hemodialysis as a Therapeutic Extracorporeal Blood Amyloid-β Removal System for Alzheimer's Disease.
    Kitaguchi N; Tatebe H; Sakai K; Kawaguchi K; Matsunaga S; Kitajima T; Tomizawa H; Kato M; Sugiyama S; Suzuki N; Mizuno M; Takechi H; Nakai S; Hiki Y; Kushimoto H; Hasegawa M; Yuzawa Y; Tokuda T
    J Alzheimers Dis; 2019; 69(3):687-707. PubMed ID: 31156161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of Amyloid-β Plasma Levels by Hemodialysis: An Anti-Amyloid Treatment Strategy?
    Tholen S; Schmaderer C; Chmielewski S; Förstl H; Heemann U; Baumann M; Steubl D; Grimmer T
    J Alzheimers Dis; 2016; 50(3):791-6. PubMed ID: 26682683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum beta-amyloid correlates with neuropsychological impairment.
    Luis CA; Abdullah L; Paris D; Quadros A; Mullan M; Mouzon B; Ait-Ghezala G; Crawford F; Mullan M
    Neuropsychol Dev Cogn B Aging Neuropsychol Cogn; 2009 Mar; 16(2):203-18. PubMed ID: 18923961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma biomarkers of Alzheimer's disease.
    Kawarabayashi T; Shoji M
    Curr Opin Psychiatry; 2008 May; 21(3):260-7. PubMed ID: 18382225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients.
    Le Bastard N; Leurs J; Blomme W; De Deyn PP; Engelborghs S
    J Alzheimers Dis; 2010; 21(1):291-301. PubMed ID: 20421698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
    Mulder SD; van der Flier WM; Verheijen JH; Mulder C; Scheltens P; Blankenstein MA; Hack CE; Veerhuis R
    J Alzheimers Dis; 2010; 20(1):253-60. PubMed ID: 20164582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma β-amyloid peptides in canine aging and cognitive dysfunction as a model of Alzheimer's disease.
    González-Martínez Á; Rosado B; Pesini P; Suárez ML; Santamarina G; García-Belenguer S; Villegas A; Monleón I; Sarasa M
    Exp Gerontol; 2011 Jul; 46(7):590-6. PubMed ID: 21377518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels.
    Abdullah L; Paris D; Luis C; Quadros A; Parrish J; Valdes L; Keegan AP; Mathura V; Crawford F; Mullan M
    Neurosci Lett; 2007 Nov; 428(2-3):53-8. PubMed ID: 17964720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.
    Fagan AM; Mintun MA; Mach RH; Lee SY; Dence CS; Shah AR; LaRossa GN; Spinner ML; Klunk WE; Mathis CA; DeKosky ST; Morris JC; Holtzman DM
    Ann Neurol; 2006 Mar; 59(3):512-9. PubMed ID: 16372280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No correlation between time-linked plasma and CSF Abeta levels.
    Le Bastard N; Aerts L; Leurs J; Blomme W; De Deyn PP; Engelborghs S
    Neurochem Int; 2009 Dec; 55(8):820-5. PubMed ID: 19695299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissociation of β-amyloid from lipoprotein in cerebrospinal fluid from Alzheimer's disease accelerates β-amyloid-42 assembly.
    Takamura A; Kawarabayashi T; Yokoseki T; Shibata M; Morishima-Kawashima M; Saito Y; Murayama S; Ihara Y; Abe K; Shoji M; Michikawa M; Matsubara E
    J Neurosci Res; 2011 Jun; 89(6):815-21. PubMed ID: 21394760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid beta-peptide levels in laser capture microdissected cornu ammonis 1 pyramidal neurons of Alzheimer's brain.
    Aoki M; Volkmann I; Tjernberg LO; Winblad B; Bogdanovic N
    Neuroreport; 2008 Jul; 19(11):1085-9. PubMed ID: 18596605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid-beta levels are significantly reduced and spatial memory defects are rescued in a novel neuroserpin-deficient Alzheimer's disease transgenic mouse model.
    Fabbro S; Schaller K; Seeds NW
    J Neurochem; 2011 Sep; 118(5):928-38. PubMed ID: 21689108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral reduction of β-amyloid is sufficient to reduce brain β-amyloid: implications for Alzheimer's disease.
    Sutcliffe JG; Hedlund PB; Thomas EA; Bloom FE; Hilbush BS
    J Neurosci Res; 2011 Jun; 89(6):808-14. PubMed ID: 21374699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.
    Aisen PS; Saumier D; Briand R; Laurin J; Gervais F; Tremblay P; Garceau D
    Neurology; 2006 Nov; 67(10):1757-63. PubMed ID: 17082468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
    Hansson O; Zetterberg H; Vanmechelen E; Vanderstichele H; Andreasson U; Londos E; Wallin A; Minthon L; Blennow K
    Neurobiol Aging; 2010 Mar; 31(3):357-67. PubMed ID: 18486992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.